Gene signatures can help doctors choose the best treatment for breast cancer patients

November 13, 2007

Gene signatures can be used to select the right treatment for patients with breast cancer, with the aim to give patients "tailored therapy" in the future, according to an Article to be published early Online and in the December issue of The Lancet Oncology.

In the study, about 44% of the patients who received chemotherapy before surgery had a pathological complete response where the tumour completely disappeared. According to the authors if gene signatures had been used to select which type of chemotherapeutic drugs to give to the patients, the response rate would have been about 70%*. The authors say: "This is such a big improvement that we need to do another study to make sure it is really true, but if it is confirmed it will make a big difference to the way doctors treat breast cancer".**

Systemic chemotherapy for the treatment of breast cancer improves overall survival. Newer chemotherapy regimens containing taxanes further improve survival compared with traditional regimens, but they are expensive, toxic, and might only benefit a small number of people, so decreasing the number of people receiving taxanes without compromising efficacy would be beneficial.

Professor Hervé Bonnefoi (Institut Bergonié, University of Bordeaux, France) and colleagues used tumour samples from patients in a large randomised multicentre trial. Patients were randomly assigned to chemotherapeutic treatments of a non-taxane regimen (fluorouracil, epirubicin, plus cyclophosphamide in the FEC group) or a taxane regimen (docetaxel followed by epirubicin plus docetaxel in the TET group). The authors calculated how well patients would respond to the two different chemotherapy treatments***. They found an excellent correlation between regimen-predictive gene signature and pathological complete response (defined as disappearance of the invasive component of the primary tumour, with at most a few scattered tumour cells detected by the pathologist in the resection specimen) in patients treated in the appropriate group. "The treatment allocation model suggests that selection of the treatment regimen with our genomic signatures has the potential to increase the pathological response rate from 44% to around 70%", say the authors.

Furthermore, the negative predictive value (NPV) for each regimen-predictive gene signature was over 90%, thus identifying patients who are unlikely to achieve a complete disappearance of the tumour after FEC or TET treatment, which include the chemotherapy drugs most commonly used to treat breast cancer. The authors note: "It would be sensible to offer these patients treatment with new drugs, by using the gene signatures to select patients for inclusion in clinical trials with new drugs or adding new drugs. By doing this, it should be possible to do much smaller trials".

The authors conclude: "If the results are confirmed in the follow-up study, then it would be well worth using our gene signatures to select the treatment for patients with breast cancer".
-end-
Professor Hervé Bonnefoi, Institut Bergonié, University of Bordeaux, France. email: bonnefoi@bergonie.org T) +33 556 33 78 17.

Notes to Editors:

*The results only apply to a subgroup of patients with tumours that are insensitive to hormonal therapy -- about 30% of patients have this sort of tumour

** All of the quotes are from the author directly and cannot be found in the text of the article

*** The mathematical formula used was developed by statisticians in Joe Nevins' group at Duke University in North Carolina, USA. They used a special form of statistics called Bayesian statisticsThe paper associated with this release can be found at
http://www.eurekalert.org/jrnls/lance/TLOgenesignatures.pdf

Lancet

Related Breast Cancer Articles from Brightsurf:

Oncotarget: IGF2 expression in breast cancer tumors and in breast cancer cells
The Oncotarget authors propose that methylation of DVDMR represents a novel epigenetic biomarker that determines the levels of IGF2 protein expression in breast cancer.

Breast cancer: AI predicts which pre-malignant breast lesions will progress to advanced cancer
New research at Case Western Reserve University in Cleveland, Ohio, could help better determine which patients diagnosed with the pre-malignant breast cancer commonly as stage 0 are likely to progress to invasive breast cancer and therefore might benefit from additional therapy over and above surgery alone.

Partial breast irradiation effective treatment option for low-risk breast cancer
Partial breast irradiation produces similar long-term survival rates and risk for recurrence compared with whole breast irradiation for many women with low-risk, early stage breast cancer, according to new clinical data from a national clinical trial involving researchers from The Ohio State University Comprehensive Cancer Center - Arthur G.

Breast screening linked to 60 per cent lower risk of breast cancer death in first 10 years
Women who take part in breast screening have a significantly greater benefit from treatments than those who are not screened, according to a study of more than 50,000 women.

More clues revealed in link between normal breast changes and invasive breast cancer
A research team, led by investigators from Georgetown Lombardi Comprehensive Cancer Center, details how a natural and dramatic process -- changes in mammary glands to accommodate breastfeeding -- uses a molecular process believed to contribute to survival of pre-malignant breast cells.

Breast tissue tumor suppressor PTEN: A potential Achilles heel for breast cancer cells
A highly collaborative team of researchers at the Medical University of South Carolina and Ohio State University report in Nature Communications that they have identified a novel pathway for connective tissue PTEN in breast cancer cell response to radiotherapy.

Computers equal radiologists in assessing breast density and associated breast cancer risk
Automated breast-density evaluation was just as accurate in predicting women's risk of breast cancer, found and not found by mammography, as subjective evaluation done by radiologists, in a study led by researchers at UC San Francisco and Mayo Clinic.

Blood test can effectively rule out breast cancer, regardless of breast density
A new study published in PLOS ONE demonstrates that Videssa® Breast, a multi-protein biomarker blood test for breast cancer, is unaffected by breast density and can reliably rule out breast cancer in women with both dense and non-dense breast tissue.

Study shows influence of surgeons on likelihood of removal of healthy breast after breast cancer dia
Attending surgeons can have a strong influence on whether a patient undergoes contralateral prophylactic mastectomy after a diagnosis of breast cancer, according to a study published by JAMA Surgery.

Young breast cancer patients undergoing breast conserving surgery see improved prognosis
A new analysis indicates that breast cancer prognoses have improved over time in young women treated with breast conserving surgery.

Read More: Breast Cancer News and Breast Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.